ECARX Zenith delivers integrated services on a single SoC, supporting Android 16, Google Automotive Services (GAS) and S-Core open-source middleware, supporting advanced software-defined vehicle architectures

LONDON, Feb. 3, 2026 /PRNewswire/ — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, debuted a pre-production sample of its Zenith computing platform at CES 2026 in Las Vegas. This innovative and ground-breaking system offers a unified high-performance intelligent cockpit and ADAS architecture, powered by the Snapdragon® Elite (SA8797) platform for automotive from Qualcomm Technologies, Inc. 

This platform reflects the latest progress in the ECARX R&D roadmap, developing a diverse portfolio of solutions to allow seamless customization for automakers for global deployment.

Developed in collaboration with Qualcomm Technologies and leveraging the powerful Qualcomm Oryon™ CPU, Qualcomm^® Adreno™ GPU and Qualcomm® Hexagon™ NPU combination, ECARX Zenith showcases the capabilities of the Snapdragon Elite platform for automotive to run mixed-criticality intelligent cockpit and ADAS functionalities simultaneously on a single, high-performance system on chip (SoC). 

The platform demonstration features an immersive, premium-feeling 3D launcher, 5K ultra-high-resolution display, and Google Automotive Services (GAS) ecosystem integration. The Zenith platform shown at CES also offers a safety-critical 3D instrument cluster display built on QNX 8.0, showcasing mixed-criticality platform support, as well as advanced Level 2++ ADAS, built on S-Core open-source middleware in collaboration with Qorix.

Beyond its current configuration, Zenith’s modular design will allow automakers to scale performance based on their tailored capability requirements. The architecture supports additional hardware modules for Level 3+ autonomy and advanced telematics, providing a long-term, upgradeable solution.

ECARX plans to use the Snapdragon Elite platform for automotive to develop a comprehensive portfolio of single-chip and flagship dual-chip integrated solutions. The Zenith computing platform is currently being demonstrated as a sample, with production expected to begin in 2027.

Mr. Ziyu Shen, Chief Executive Officer and Chairman of ECARX, commented, “ECARX has been committed to the development of cutting-edge automotive intelligent technologies since inception. ‌CES provided an opportunity for ECARX and our partners to show not just how our platforms are already delivering value to drivers and automakers in the 10 million+ vehicles on the road worldwide with our technologies, but also the enormous possibilities our innovative R&D roadmap is creating.

“With Qualcomm Technologies’ Snapdragon Elite platform for automotive, we believe the power and modular flexibility of the Zenith computing platform will make it a cornerstone for automakers building the next generation of automotive experiences. We look forward to driving further innovation and new breakthroughs together with our eco-partners on a global scale.”

Qualcomm, Adreno, Hexagon, Qualcomm Oryon and Snapdragon are trademarks or registered trademarks of Qualcomm Incorporated.
Snapdragon, Qualcomm Oryon, Qualcomm Adreno and Qualcomm Hexagon are products of Qualcomm Technologies, Inc. and/or its subsidiaries.

About ECARX

ECARX (Nasdaq: ECX) is a global automotive technology provider with capabilities to deliver turnkey solutions for next–generation smart vehicles, from the system–on–a–chip (SoC) to central computing platforms and software. As automakers develop new vehicle architectures, ECARX is developing full–stack solutions to enhance the user experience while reducing complexity and cost.

Founded in 2017 and listed on the Nasdaq in 2022, ECARX now has over 1,500 employees based in 13 major locations in China, UK, USA, Brazil, Singapore, Malaysia, Sweden and Germany. To date, ECARX products can be found in approximately 10 million vehicles worldwide.

SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ — On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterprises to participate in the event.

Hosted by bioSeedin and centered on the theme “Global Matching of Innovative Assets,” the summit brought together multinational pharmaceuticals, investors, and emerging biotech companies to explore licensing opportunities and globalization strategies for innovative therapeutics. Over 500 delegates from more than ten countries and regions engaged in vibrant discussions, fostering extensive collaborative intentions. The event was also sponsored by Lilly, Roche, and Fangda Partners.

Committed to being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models, ACROBiosystems, against the backdrop of a new era defined by “capital + collaboration” in global medical innovation, embraced the brand proposition of “Connecting the world, your partner from discovery to the clinic.” Through this summit, ACROBiosystems aimed to link resources, facilitate strategic partnerships, and empower global innovation.

In parallel with this vision, ACROBiosystems is committed to delivering reliable quality and considerate service.

ACROBiosystems set up a dedicated networking lounge at the summit, conducting in-depth dialogues with global pharmaceutical and biotech pioneers. Discussions focused on the global expansion pathway for locally-developed innovative drugs, addressing critical topics such as license-in/out cooperation, global clinical development, and market access, resulting in efficient and practical resource alignment for mutual value creation.

Industry Spotlight: Global Strategies and Local Innovations

Oncology Session: Panelists highlighted China’s unique advantages in clinical speed, platform iteration, and portfolio strategy, predicting globally competitive innovations in ADC, TCE, and novel cell/gene therapies in the coming years.

Cardio-Renal-Metabolic Session: Experts emphasized de-risking clinical trials and recognized small biotech as the core driver of innovation, with MNCs leveraging distinct advantages in the cardiovascular market.

Autoimmune Session: Discussions centered on betting on FIC targets, with insights on smarter deal structures, regional stratification, and global coordination to accelerate value delivery.

The sessions featured senior leaders from leading global pharmaceutical companies, investment firms, and biotech organizations as moderators and panelists, including representatives from Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS, and Fangda Partners.

Companies including Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife Pharmaceuticals, Innovative Cellular Therapeutics, Huaota Biopharmaceutical, Leads Biolabs, Youcare Pharmaceutical, Sciwind Biosciences, HighTide Therapeutics, Sirius Therapeutics, Alphamab, ImmuneOnco Biopharmaceuticals, Genrix Biopharmaceutical, Mabwell Bioscience, VelaVigo Bio, and Degron Therapeutics presented pipelines covering antibodies, bispecifics, TCE, ADC, molecular glues, the neuro-metabolic field, and more, drawing keen interest from attendees.

About ACROBiosystems Group

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.

BEIJING, Feb. 2, 2026 /PRNewswire/ — Elong Power Holding Limited (Nasdaq: ELPW) (“Elong Power” or the “Company”), a provider of high power battery technologies for commercial and specialty alternative energy vehicles and energy storage systems, today announced the pricing of its underwritten public offering (the “Offering”) of 2,400,000 Units on a firm commitment basis, at a price of US$3.16 per Unit. Each Unit consists of one Class A ordinary share, par value of US$0.00016 per share (each a “Class A Ordinary Share”), of the Company (or one pre-funded warrant (each a “Pre-Funded Warrant”) to purchase one Class A Ordinary Share in lieu thereof) and one common warrant (each a “Common Warrant”) to purchase one Class A Ordinary Share. Gross proceeds to the Company, before deducting underwriting discounts and other offering expenses, are expected to be approximately US$7.6million.

Each Common Warrant will expire three years from the date of issuance, and is exercisable immediately on the date of issuance at an exercise price of US$3.16 per share, subject to adjustment on the 4^th and 8^th trading days following the closing of this Offering to the price that is equal to 70% and 50%, respectively, of the initial exercise price of the Common Warrants, and the number of Class A Ordinary Shares underlying the Common Warrants will be proportionately increased. The Common Warrants may, at any time following the closing of this Offering and in the holders’ sole discretion, be exercised in whole or in part by means of a zero exercise price option, in which the holders will receive twice the number of Class A Ordinary Shares that would be issuable upon a cash exercise of the Common Warrant, without payment of additional consideration.

The Offering is expected to close on February 3, 2026, subject to customary closing conditions. The Company intends to use the proceeds from the Offering for 1) general corporate purposes and working capital, 2) sales network expansion, including the hiring of sale personnel and the development of regional sales channels, and 3) expansion of production and capacity, including new equipment and upgrades to its manufacturing facilities.

The Company has granted the underwriters a 45-day option to purchase up to an additional 360,000 Class A Ordinary Shares and/or additional 360,000 Common Warrants, at its respective public offering price less underwriting discounts and commissions.

Maxim Group LLC is acting as the exclusive underwriter. Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Pryor Cashman LLP is acting as U.S. securities counsel to the underwriter, in connection with the Offering.

A registration statement on F-1 (File No. 333-292937) was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on January 29, 2026. The Offering is being made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Elong Power

Elong Power Holding Limited, a Cayman Islands exempted company, is committed to the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. Elong Power is led by Ms. Xiaodan Liu, Elong Power’s Chairwoman and CEO.

Elong Power has a comprehensive product and technology system that includes battery cells, modules, system integration, and battery management system development, based on high-power lithium-ion batteries and battery system products for long-cycle energy storage devices. Elong Power offers advanced energy applications and full life cycle services. Its product portfolio includes products utilizing lithium manganese oxide and lithium iron phosphate, among others, to meet the needs of high-power applications and energy storage applications in various scenarios.

Forward-looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the products offered by Elong Power and the markets in which it operates, and Elong Power’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: the ability of Elong Power to maintain the listing of its securities on Nasdaq; the fact that the price of Elong Power’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Elong Power operates; variations in performance across competitors; changes in laws and regulations affecting Elong Power’s business and changes in its capital structure; the ability to implement business plans, meet forecasts and other expectations; its need for substantial additional funds; the parties’ dependence on third-party suppliers; risks relating to the results of research and development activities, market and other conditions; its ability to attract, integrate, and retain key personnel; risks related to its growth strategy; risks related to patent and intellectual property matters; and the ability to obtain, perform under and maintain financing and strategic agreements and relationships. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Elong Power’s business are described in detail in Elong Power’s SEC filings which are available on the SEC’s website at www.sec.gov, including in Elong Power’s Annual Report on Form 20-F and Elong Power’s subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and Elong Power expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

For investor and media inquiries, please contact:

Elong Power Investor Contact
ir@elongpower.com